Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
02:07pm, Tuesday, 22'nd Oct 2024
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analys
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
09:20am, Tuesday, 22'nd Oct 2024
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight r
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
08:45am, Thursday, 17'th Oct 2024
Novartis is taking a more calculated and strategic approach to its growth.
Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weigh
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
04:05pm, Tuesday, 15'th Oct 2024
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral coval
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
09:30am, Sunday, 13'th Oct 2024
The future of the weight loss market might not revolve around GLP-1 drugs.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
04:12pm, Wednesday, 09'th Oct 2024
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares s
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
09:05am, Wednesday, 09'th Oct 2024
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company
WeightWatchers' stock soars after adding compounded GLP-1 treatment to its offering
10:38am, Tuesday, 08'th Oct 2024
“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Exe
GLP Capital Partners and Ares Management Corp to Merge in $5.2 Billion Deal
10:31am, Tuesday, 08'th Oct 2024
GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York
Lexaria Updates Current GLP-1 Market
09:20am, Tuesday, 08'th Oct 2024
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on
Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)
02:10am, Monday, 07'th Oct 2024
Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to musc
Midstream Energy - Relative Quality
07:37am, Friday, 04'th Oct 2024
Many midstream energy companies pay stable, well-supported distributions or dividends with yields well over 5%. The relative quality of twenty-nine midstream energy companies was evaluated by means of
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
08:30am, Thursday, 03'rd Oct 2024
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and well
